IPSC logo

CENTURY THERAPEUTICS INC

IPSCNASDAQ
🏆 #3374 by market capEarnings Nov 5 · PreUS Equity
$1.50▲ $0.06 (+4.17%)
Market closed · at close
🔔
Track IPSC
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 4.2%
7d▼ 4.8%
14d▲ 0.0%
30d▼ 8.8%
ytd▲ 53.6%
1y▲ 162.1%
🏦Market Cap
$272M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
2.3x
Cheap
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$1.43 – $1.50
52-Week Range
$0.44 – $3.04
Volume (shares)
133,361
Avg Volume (shares)
—
Shares Outstanding
181.1M
Next Earnings
2026-11-05

Fundamentals Snapshot

Annual Revenue
$109M
Last Q Revenue
—
P/E Ratio
—
P/S Ratio
2.3x
EPS (TTM)
$-0.90
Dividend Yield
—
Dilution (1yr)
+10.1%
IPSC logo

CENTURY THERAPEUTICS INC

IPSC
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$109M▲ +1556.8% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
88.0%▼ −12.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$15M▼ −89.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$105M▼ −5.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
86.6M▲ +10.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$18M▲ +$14M YoY
StockOtter · stockotter.space

About CENTURY THERAPEUTICS INC

Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100

Analyst Ratings

ⓘ
Consensus
Buy
12 analysts
Strong Buy2
Buy8
Hold2
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.